Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein

Our findings present a novel mouse model for glioma demonstrating that the PI3K pathway is important for initiation of tumorigenesis

Research

Tissue-resident memory T cells orchestrate tumour-immune equilibrium

Our findings provide insight into the immune cell populations important for maintaining long-term tumour dormancy in peripheral tissues

Sarcoma Translational Research

We aim to discover and develop safer and more effective treatments by doing inventive and rigorous research to improve outcomes for kids with cancer.

Research

A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma

We present a curated panel of 12 readily-usable, cell lines representing the spectrum of molecular subtypes of IDH-wildtype glioblastoma

Research

Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response

Despite low ERBB4 mRNA in glioblastoma, the functional effects of increased ERBB4 activation identify ERBB4 as a potential prognostic and therapeutic target

Research

Optimal conditions required for influenza A infection-enhanced cross-priming of CD8+ T cells specific to cell-associated antigens

Our group has recently shown that influenza A virus (IAV) infection of allogeneic cells lead to enhanced cross-priming of TCD8+ specific to cellular antigens.

Research

Dendritic cells and influenza A virus infection

Influenza A virus (IAV) is a dangerous virus equipped with the potential to evoke widespread pandemic disease.

Research

Role of COL5A1 in lung squamous cell Carcinoma: Prognostic Implications and therapeutic potential

Lung squamous cell carcinoma (LUSC) is a significant health concern, characterized by a lack of specific therapies and limited treatment options for patients in advanced stages. This study aims to identify key molecules of prognostic importance in LUSC and provide an experimental foundation for their potential therapeutic applications.

Research

CD4+ T cells drive an inflammatory, TNF-α/IFN-rich tumor microenvironment responsive to chemotherapy

While chemotherapy remains the first-line treatment for many cancers, it is still unclear what distinguishes responders from non-responders. Here, we characterize the chemotherapy-responsive tumor microenvironment in mice, using RNA sequencing on tumors before and after cyclophosphamide, and compare the gene expression profiles of responders with progressors.

Research

IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies

Cancer vaccination drives the generation of anti-tumor T cell immunity and can be enhanced by the inclusion of effective immune adjuvants such as type I interferons (IFNs). Whilst type I IFNs have been shown to promote cross-priming of T cells, the role of individual subtypes remains unclear. Here we systematically compared the capacity of distinct type I IFN subtypes to enhance T cell responses to a whole-cell vaccination strategy in a pre-clinical murine model.